What is the best treatment for hidradenitis suppurativa?

Best Treatment for Hidradenitis Suppurativa

For moderate-to-severe hidradenitis suppurativa, adalimumab (40 mg weekly) is the first-line systemic therapy, as it is the only FDA-approved biologic with proven efficacy in phase 3 trials, achieving clinical response in 42-59% of patients at 12 weeks. 1

Treatment Algorithm by Disease Severity

Moderate-to-Severe Disease (Primary Recommendation)

Adalimumab remains the cornerstone of therapy for moderate-to-severe HS. 1

• Dosing regimen: 160 mg at week 0,80 mg at week 2, then 40 mg weekly starting at week 4 1
• Expected outcomes: The PIONEER trials demonstrated HiSCR response rates of 42% (PIONEER 1) and 59% (PIONEER 2) versus 26-28% with placebo at 12 weeks 1
• Critical timing consideration: Nearly 40% of initial non-responders at 12 weeks achieved response by 36 weeks with continued treatment, so persistence beyond initial assessment is warranted 1
• Important caveat: Almost half of week 12 responders lost response at week 36 despite weekly maintenance dosing, indicating need for ongoing monitoring and potential treatment adjustments 1

Newer FDA-Approved Options

Secukinumab (IL-17A inhibitor) and bimekizumab (dual IL-17A/F inhibitor) have recently been approved, expanding treatment options beyond TNF inhibition. 2, 3

• These represent important alternatives for adalimumab non-responders or those who lose response over time 3
• The IL-17 pathway targeting addresses a distinct immunologic mechanism in HS pathogenesis 2

Second-Line Biologic Therapy

Infliximab should be considered when adalimumab fails or is inadequate. 1

• Dosing: 5 mg/kg at weeks 0,2, and 6, then every 8 weeks, though expert experience suggests titration to 10 mg/kg every 4-8 weeks may be necessary for optimal control 1
• Evidence: Post-hoc analyses showed 13 of 15 patients (87%) achieved ≥25% improvement in severity scores at week 8 1
• Real-world data: Case series demonstrated 78% response rate (defined as ≥50% decrease in HS score) in 55 of 71 patients 1
• Limitation: The primary endpoint (50% decrease in severity) did not reach statistical significance in the controlled trial (P = 0.092) 1

Adjunctive and Bridge Therapy

Systemic corticosteroids serve as effective rescue therapy for acute flares or bridging to long-term treatment. 1

• Dosing: Prednisone 0.5-1 mg/kg daily as pulses or multiweek tapers 1
• Efficacy: In 13 patients with moderate-to-severe HS, 46% had partial response and 38% had good response with addition of 10 mg prednisone to existing treatment 1
• Critical note: All 5 patients who initially did not respond to adalimumab showed improvement with prednisone addition 1
• Limitation: Side effects limit prolonged use; this is strictly short-term therapy 1

Concomitant tetracycline-class antibiotics can be continued with biologic therapy. 1

• In PIONEER 2,19% of patients continued tetracycline-class antibiotics during adalimumab treatment 1

Therapies NOT Recommended Based on Evidence

Avoid methotrexate, azathioprine, cyclosporine (at doses <5 mg/kg), and colchicine monotherapy due to poor efficacy data. 1

• Methotrexate showed no efficacy in 3 patients treated for 6-24 weeks 1
• Azathioprine at low doses (0.5-1 mg/kg) showed only slight improvement in 4 of 9 patients 1
• Cyclosporine responses were generally poor at doses <5 mg/kg, with frequent relapse upon discontinuation and limiting side effects 1
• Colchicine monotherapy is not supported by evidence, though combination with minocycline showed some benefit 1

Multimodal Treatment Strategy

HS management requires treatment stacking that combines medical and surgical approaches based on disease phase. 4

• Inflammatory phase: Drug therapy alone 2
• Destructive phase: Combined drug and surgical therapy 2
• Burnout phase: Surgery alone 2

Early intervention is critical to prevent irreversible skin damage, tunnel formation, and morbid scarring. 2

Emerging Therapies

A robust pipeline of immunomodulatory drugs targeting IL-1, IL-12/Th1, and IL-23/Th17 pathways is in various stages of development. 1, 5

• These represent future options for refractory disease or patients who fail current approved therapies 5

Comorbidity Management

Screen for and address metabolic syndrome, inflammatory arthritis, and inflammatory bowel disease, as systemic inflammation drives these comorbidities. 2

• HS has profound negative effects on quality of life and requires holistic, interdisciplinary management 2, 6

Common Pitfalls

• Premature discontinuation of adalimumab: Continue treatment beyond 12 weeks even in apparent non-responders, as 40% may achieve response by 36 weeks 1
• Inadequate infliximab dosing: Standard 5 mg/kg every 8 weeks may be insufficient; consider escalation to 10 mg/kg every 4-8 weeks 1
• Using ineffective immunosuppressants: Avoid wasting time on methotrexate, low-dose azathioprine, or colchicine monotherapy 1
• Delayed diagnosis: HS is often underdiagnosed despite being one of the most quality-of-life-impairing dermatologic conditions 6